Trial reportJournal of hypertension2015
Time of administration important? Morning versus evening dosing of valsartan.
Trial report in Journal of hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00241124 (A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension And Non-Insulin Dependent Diabetes), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension And Non-Insulin Dependent Diabetes
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Chronotherapy for Hypertension: A Meta-Analysis and Systematic Review of RCTs.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Pooled it
- Evening versus morning dosing regimen drug therapy for hypertension.The Cochrane database of systematic reviews · 2024Pooled it
- Chronotherapy for morning blood pressure surge in hypertensive patients: a systematic review and meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- Population Pharmacokinetic Modeling Practice of Time-Varying Clearance: Insights from a First-in-Human Study Case.Journal of clinical pharmacology · 2026Trial
- Morning vs Bedtime Dosing and Nocturnal Blood Pressure Reduction in Patients With Hypertension: The OMAN Randomized Clinical Trial.JAMA network open · 2025Trial
- Comparison of morning vs bedtime administration of the combination of valsartan/amlodipine on nocturnal brachial and central blood pressure in patients with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Valsartan Mitigates the Progression of Methotrexate-Induced Acute Kidney Injury in Rats via the Attenuation of Renal Inflammation and Oxidative Stress.Journal of inflammation research · 2024Article
- Statement on chronotherapy for the treatment of hypertension: consensus document from the Korean society of hypertension.Clinical hypertension · 2023Review
- Pharmacotherapy for Essential Hypertension: A Brief Review.Methodist DeBakey cardiovascular journal · 2022Review
- Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications: Controversies in Hypertension - Con Side of the Argument.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Article
- Characteristics and control of the 24-hour ambulatory blood pressure in patients with metabolic syndrome.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- New Insights Into Cancer Chronotherapies.Frontiers in pharmacology · 2021Review
- Dosing Time Matters? Nighttime vs. Daytime Administration of Nifedipine Gastrointestinal Therapeutic System (GITS) or Amlodipine on Non-dipper Hypertension: A Randomized Controlled Trial of NARRAS.Frontiers in cardiovascular medicine · 2021Article
- Does Timing of Antihypertensive Medication Dosing Matter?Current cardiology reports · 2020Review
- Chronotherapy for Hypertension.Current hypertension reports · 2018Review
- Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects.Integrated blood pressure control · 2018Review
- Secondary Stroke Prevention: Improving Diagnosis and Management with Newer Technologies.Translational stroke research · 2016Review
- Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStudies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction. We compared the antihypertensive effects of morning (a.m.) and evening (p.m.) dosing of valsartan on 24-h BP.
methodsThis 26-week, multicentre, randomized, double-blind study evaluated the efficacy and safety of valsartan 320 mg, dosed a.m. or p.m., versus lisinopril 40 mg (a.m.), a long-acting ACE-inhibitor, in patients with grade 1-2 hypertension and at least one additional cardiovascular risk factor. Patients (n = 1093; BP = 156 ± 11/91 ± 8 mmHg; 62 years, 56% male, 99% white) received (1 : 1 : 1) valsartan 160 mg a.m. or p.m. or lisinopril 20 mg a.m. for 4 weeks, then force-titrated to double the initial dose for 8 weeks. At Week 12, hydrochlorothiazide (HCTZ) 12.5 mg was added for 14 weeks if office BP was more than 140/90 mmHg and/or ambulatory BP more than 130/80 mmHg.
resultsMean 24-h ambulatory SBP change from baseline to Weeks 12 and 26 was comparable between valsartan a.m. (-10.6 and -13.3 mmHg) and p.m. (-9.8 and -12.3 mmHg) and lisinopril (-10.7 and -13.7 mmHg). There was no benefit of valsartan p.m. versus a.m. on night-time BP, early morning BP and morning BP surge. Evening dosing also did not improve BP lowering in patients requiring add-on HCTZ or in nondippers at baseline. All treatments were well tolerated.
conclusionOnce-daily dosing of valsartan 320 mg results in equally effective 24-h BP efficacy, regardless of dosing time.
trial registrationClinicalTrials.gov Identifier: NCT00241124.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.